Ohr Pharmaceuticals Company Profile (NASDAQ:OHRP)

About Ohr Pharmaceuticals (NASDAQ:OHRP)

Ohr Pharmaceuticals logoOHR Pharmaceutical, Inc., a pharmaceutical company, focuses on the development of novel therapeutics and delivery technologies for the treatment of ocular disease. Its lead clinical program is topical Squalamine, a small molecule anti-angiogenic drug, which could provide a non-invasive therapy to enhance vision outcomes. The company is evaluating Squalamine, which completed Phase II clinical trials for the treatment of retinal diseases, including wet-AMD, proliferative diabetic retinopathy, and retinal vein occlusion. Its preclinical pipeline of sustained release programs include sustained release formulations of small molecule and protein therapeutics for the treatment of ocular diseases, such as glaucoma, steroid induced glaucoma, ocular allergy, and retinal disease. OHR Pharmaceutical, Inc. is headquartered in New York, New York.

Industry, Sector and Symbol: Capitalization:
  • Market Cap: $42.72 million
  • Outstanding Shares: 56,211,000
Average Prices:
  • 50 Day Moving Avg: $0.70
  • 200 Day Moving Avg: $0.70
  • 52 Week Range: $0.56 - $4.05
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -0.68
  • P/E Growth: -0.02
Sales & Book Value:
  • Annual Revenue: N/A
  • Price / Sales: N/A
  • Book Value: $0.50 per share
  • Price / Book: 1.52
Profitability:
  • EBIDTA: ($24,220,000.00)
  • Return on Equity: -103.56%
  • Return on Assets: -85.09%
Debt:
  • Current Ratio: 3.31%
  • Quick Ratio: 3.31%
Misc:
  • Average Volume: 221,616 shs.
  • Beta: 0.6
  • Short Ratio: 6.29
 

Frequently Asked Questions for Ohr Pharmaceuticals (NASDAQ:OHRP)

What is Ohr Pharmaceuticals' stock symbol?

Ohr Pharmaceuticals trades on the NASDAQ under the ticker symbol "OHRP."

How were Ohr Pharmaceuticals' earnings last quarter?

Ohr Pharmaceuticals, Inc. (NASDAQ:OHRP) issued its quarterly earnings data on Tuesday, August, 8th. The company reported ($0.07) EPS for the quarter, beating the Zacks' consensus estimate of ($0.25) by $0.18. View Ohr Pharmaceuticals' Earnings History.

When will Ohr Pharmaceuticals make its next earnings announcement?

Ohr Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, December, 20th 2017. View Earnings Estimates for Ohr Pharmaceuticals.

Where is Ohr Pharmaceuticals' stock going? Where will Ohr Pharmaceuticals' stock price be in 2017?

2 equities research analysts have issued 1-year price objectives for Ohr Pharmaceuticals' stock. Their forecasts range from $10.00 to $10.00. On average, they expect Ohr Pharmaceuticals' stock price to reach $10.00 in the next year. View Analyst Ratings for Ohr Pharmaceuticals.

Who are some of Ohr Pharmaceuticals' key competitors?

Who owns Ohr Pharmaceuticals stock?

Ohr Pharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (1.45%) and Cannell Peter B & Co. Inc. (0.52%). Company insiders that own Ohr Pharmaceuticals stock include Jason Scott Slakter, Orin Hirschman and Samuel Backenroth. View Institutional Ownership Trends for Ohr Pharmaceuticals.

Who bought Ohr Pharmaceuticals stock? Who is buying Ohr Pharmaceuticals stock?

Ohr Pharmaceuticals' stock was purchased by a variety of institutional investors in the last quarter, including Cannell Peter B & Co. Inc. and Vanguard Group Inc.. Company insiders that have bought Ohr Pharmaceuticals stock in the last two years include Jason Scott Slakter, Orin Hirschman and Samuel Backenroth. View Insider Buying and Selling for Ohr Pharmaceuticals.

How do I buy Ohr Pharmaceuticals stock?

Shares of Ohr Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Ohr Pharmaceuticals' stock price today?

One share of Ohr Pharmaceuticals stock can currently be purchased for approximately $0.76.


MarketBeat Community Rating for Ohr Pharmaceuticals (NASDAQ OHRP)
Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  135 (Vote Outperform)
Underperform Votes:  80 (Vote Underperform)
Total Votes:  215
MarketBeat's community ratings are surveys of what our community members think about Ohr Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Ohr Pharmaceuticals (NASDAQ:OHRP) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Hold Rating, 1 Buy Rating
Consensus Rating:Buy (Score: 2.50)
Consensus Price Target: $10.00 (1,215.79% upside)

Analysts' Ratings History for Ohr Pharmaceuticals (NASDAQ:OHRP)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
8/16/2017HC WainwrightSet Price TargetBuy$10.00HighView Rating Details
10/4/2016Brean CapitalInitiated CoverageHoldN/AView Rating Details
6/16/2016Roth CapitalReiterated RatingBuy$13.00N/AView Rating Details
5/16/2016Chardan CapitalReiterated RatingHoldN/AView Rating Details
(Data available from 9/23/2015 forward)

Earnings

Earnings History for Ohr Pharmaceuticals (NASDAQ:OHRP)
Earnings by Quarter for Ohr Pharmaceuticals (NASDAQ:OHRP)
Earnings History by Quarter for Ohr Pharmaceuticals (NASDAQ OHRP)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
12/20/2017N/AView Earnings Details
8/8/2017Q3 2017($0.25)($0.07)ViewListenView Earnings Details
5/11/2017Q2 2017($0.30)($0.21)ViewN/AView Earnings Details
2/14/2017Q117($0.19)($0.21)ViewListenView Earnings Details
5/10/2016Q2($0.18)($0.17)ViewListenView Earnings Details
12/10/2015Q415($0.20)($0.13)ViewListenView Earnings Details
5/11/2015Q215($0.17)($0.12)ViewListenView Earnings Details
2/9/2015Q115($0.20)($0.18)ViewN/AView Earnings Details
12/22/2014($0.10)($0.12)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Ohr Pharmaceuticals (NASDAQ:OHRP)
Current Year EPS Consensus Estimate: $-0.74 EPS
Next Year EPS Consensus Estimate: $-1.12 EPS

Dividends

Dividend History for Ohr Pharmaceuticals (NASDAQ:OHRP)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Ohr Pharmaceuticals (NASDAQ:OHRP)
Insider Ownership Percentage: 17.40%
Institutional Ownership Percentage: 7.02%
Insider Trades by Quarter for Ohr Pharmaceuticals (NASDAQ:OHRP)
Institutional Ownership by Quarter for Ohr Pharmaceuticals (NASDAQ:OHRP)
Insider Trades by Quarter for Ohr Pharmaceuticals (NASDAQ:OHRP)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
4/10/2017Orin HirschmanDirectorBuy142,858$0.70$100,000.60View SEC Filing  
4/10/2017Samuel BackenrothCFOBuy71,429$0.70$50,000.30View SEC Filing  
6/20/2016Jason Scott SlakterCEOBuy8,786$2.85$25,040.10View SEC Filing  
6/20/2016Samuel BackenrothCFOBuy2,468$2.84$7,009.12View SEC Filing  
5/25/2016Jason Scott SlakterCEOBuy3,682$3.11$11,451.02View SEC Filing  
5/24/2016Jason Scott SlakterCEOBuy28,068$3.15$88,414.20View SEC Filing  
5/23/2016Samuel BackenrothCFOBuy2,500$3.17$7,925.00View SEC Filing  
4/11/2016Jason Scott SlakterCEOBuy6,250$3.35$20,937.50View SEC Filing  
3/7/2016Jason Scott SlakterCEOBuy6,250$3.63$22,687.50View SEC Filing  
2/22/2016Jason Scott SlakterCEOBuy6,250$3.11$19,437.50View SEC Filing  
1/19/2016Jason Scott SlakterCEOBuy6,250$3.62$22,625.00View SEC Filing  
12/7/2015Jason Scott SlakterCEOBuy3,000$4.07$12,210.00View SEC Filing  
11/3/2015Jason Scott SlakterCEOBuy13,350$3.00$40,050.00View SEC Filing  
2/6/2015Irach B TaraporewalaCEOBuy3,705$6.75$25,008.75View SEC Filing  
2/6/2015June Sherie AlmenoffDirectorBuy6,000$6.75$40,500.00View SEC Filing  
2/6/2015Samuel BackenrothCFOBuy1,500$6.75$10,125.00View SEC Filing  
9/3/2014June Sherie AlmenoffDirectorBuy2,200$8.08$17,776.00View SEC Filing  
7/2/2014Ira A GreensteinDirectorBuy1,000$8.40$8,400.00View SEC Filing  
6/26/2014June Sherie AlmenoffDirectorBuy3,200$8.34$26,688.00View SEC Filing  
6/25/2014Thomas M RiedhammerDirectorBuy6,900$7.39$50,991.00View SEC Filing  
4/9/2014Ira A GreensteinDirectorBuy2,500$10.20$25,500.00View SEC Filing  
4/8/2014June Sherie AlmenoffDirectorBuy5,500$10.25$56,375.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Ohr Pharmaceuticals (NASDAQ:OHRP)
Latest Headlines for Ohr Pharmaceuticals (NASDAQ:OHRP)
Source:
DateHeadline
americanbankingnews.com logoOhr Pharmaceuticals (OHRP) & Its Competitors Head to Head Analysis
www.americanbankingnews.com - September 20 at 6:08 PM
americanbankingnews.com logoFinancial Comparison: Ohr Pharmaceuticals (OHRP) and Its Peers
www.americanbankingnews.com - September 15 at 9:02 AM
finance.yahoo.com logoWhat Is Ohr Pharmaceutical Inc’s (OHRP) Share Price Doing?
finance.yahoo.com - September 15 at 7:09 AM
businesswire.com logoSHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Concerning Possible Breaches of ... - Business Wire (press release)
www.businesswire.com - September 13 at 7:23 AM
americanbankingnews.com logo Brokerages Anticipate Ohr Pharmaceuticals, Inc. (OHRP) to Post -$0.07 Earnings Per Share
www.americanbankingnews.com - September 12 at 12:26 PM
finance.yahoo.com logoSHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Ohr Pharmaceutical, Inc.
finance.yahoo.com - September 12 at 8:12 AM
americanbankingnews.com logoReviewing Ohr Pharmaceuticals (OHRP) & its Peers
www.americanbankingnews.com - September 11 at 6:24 PM
americanbankingnews.com logoZacks: Analysts Anticipate OHR Pharmaceutical Inc (OHRP) Will Announce Earnings of -$0.07 Per Share
www.americanbankingnews.com - August 25 at 2:26 AM
americanbankingnews.com logoOhr Pharmaceuticals, Inc. (OHRP) Upgraded to Strong-Buy by Zacks Investment Research
www.americanbankingnews.com - August 19 at 10:20 AM
americanbankingnews.com logoHC Wainwright Analysts Give Ohr Pharmaceuticals, Inc. (OHRP) a $10.00 Price Target
www.americanbankingnews.com - August 16 at 8:02 AM
americanbankingnews.com logoHead to Head Comparison: Ohr Pharmaceuticals (NASDAQ:OHRP) & Aevi Genomic Medicine (GNMX)
www.americanbankingnews.com - August 10 at 10:24 PM
americanbankingnews.com logoOhr Pharmaceuticals, Inc. (OHRP) Issues Earnings Results, Beats Estimates By $0.18 EPS
www.americanbankingnews.com - August 9 at 5:22 PM
cnbc.com logoOHR reports 3Q loss
www.cnbc.com - August 9 at 6:05 AM
cnbc.com logoOHR reports 3Q loss
www.cnbc.com - August 9 at 6:05 AM
finance.yahoo.com logoOhr Pharmaceutical Announces Fiscal Third Quarter 2017 Earnings
finance.yahoo.com - August 9 at 6:05 AM
finance.yahoo.com logoOhr Pharmaceutical Announces Fiscal Third Quarter 2017 Earnings
finance.yahoo.com - August 9 at 6:05 AM
americanbankingnews.com logoTetralogic Pharmaceuticals Corp (TLOG) and Ohr Pharmaceuticals (OHRP) Critical Contrast
www.americanbankingnews.com - August 8 at 10:18 PM
finance.yahoo.com logoOhr Pharmaceutical to Announce Fiscal Third Quarter 2017 Results on August 8
finance.yahoo.com - August 1 at 12:11 AM
americanbankingnews.com logoZacks Investment Research Lowers Ohr Pharmaceuticals, Inc. (NASDAQ:OHRP) to Hold
www.americanbankingnews.com - July 23 at 11:25 AM
americanbankingnews.com logoMateon Therapeutics (MATN) & Ohr Pharmaceuticals (OHRP) Financial Comparison
www.americanbankingnews.com - July 19 at 10:45 AM
americanbankingnews.com logo Analysts Expect Ohr Pharmaceuticals, Inc. (OHRP) to Post -$0.25 Earnings Per Share
www.americanbankingnews.com - July 17 at 2:30 PM
americanbankingnews.com logoOhr Pharmaceuticals, Inc. (OHRP) Expected to Post Earnings of -$0.25 Per Share
www.americanbankingnews.com - June 21 at 10:18 AM
seekingalpha.com logoOhr Pharmaceutical (OHRP) Presents At 2017 Marcum Microcap Conference - Slideshow
seekingalpha.com - June 16 at 7:59 PM
finance.yahoo.com logoOhr Pharmaceutical to Present at the 2017 Marcum Microcap Conference
finance.yahoo.com - June 12 at 6:41 PM
americanbankingnews.com logo-$0.25 EPS Expected for OHR Pharmaceutical Inc (OHRP) This Quarter
www.americanbankingnews.com - May 26 at 7:37 AM
americanbankingnews.com logoOHR Pharmaceutical Inc (OHRP) Issues Earnings Results
www.americanbankingnews.com - May 12 at 11:06 AM
streetinsider.com logoOhr Pharmaceutical (OHRP) Announces Appointment of Mike Ferguson as Chairman of the Board of Directors
www.streetinsider.com - May 12 at 12:32 AM
cnbc.com logoOHR reports 2Q loss
www.cnbc.com - May 11 at 7:30 PM
finance.yahoo.com logoInvestor Network: Ohr Pharmaceutical Inc to Host Earnings Call
finance.yahoo.com - May 11 at 7:30 PM
finance.yahoo.com logoOhr Pharmaceutical Announces Fiscal Second Quarter 2017 Earnings
finance.yahoo.com - May 11 at 7:30 PM
finance.yahoo.com logoOhr Pharmaceutical Announces Appointment of Hon. Mike Ferguson as Chairman of the Board of Directors
finance.yahoo.com - May 11 at 7:30 PM
finance.yahoo.com logoOhr Pharmaceutical to Announce Fiscal Second Quarter 2017 Results on May 11
finance.yahoo.com - May 9 at 11:20 AM
americanbankingnews.com logo-$0.30 EPS Expected for OHR Pharmaceutical Inc (OHRP) This Quarter
www.americanbankingnews.com - May 3 at 12:06 AM
americanbankingnews.com logoOHR Pharmaceutical (OHRP) Receiving Somewhat Favorable News Coverage, AlphaOne Reports
www.americanbankingnews.com - May 2 at 9:52 AM
americanbankingnews.com logoSomewhat Positive Media Coverage Very Likely to Affect OHR Pharmaceutical (OHRP) Stock Price
www.americanbankingnews.com - April 29 at 6:11 PM
americanbankingnews.com logoOHR Pharmaceutical (OHRP) Earns Coverage Optimism Score of 0.05
www.americanbankingnews.com - April 21 at 6:04 PM
finance.yahoo.com logoOhr Pharmaceutical (OHRP) Jumps: Stock Adds 15% in Session
finance.yahoo.com - April 18 at 9:59 AM
americanbankingnews.com logoSomewhat Positive Media Coverage Extremely Likely to Effect OHR Pharmaceutical (OHRP) Stock Price
www.americanbankingnews.com - April 17 at 1:47 PM
americanbankingnews.com logoOHR Pharmaceutical (OHRP) Getting Somewhat Favorable News Coverage, AlphaOne Reports
www.americanbankingnews.com - April 14 at 2:24 PM
americanbankingnews.com logoOHR Pharmaceutical Inc (OHRP) CFO Samuel Backenroth Buys 71,429 Shares
www.americanbankingnews.com - April 13 at 2:26 PM
americanbankingnews.com logoOHR Pharmaceutical Inc (OHRP) Director Purchases $100,000.60 in Stock
www.americanbankingnews.com - April 13 at 2:26 PM
americanbankingnews.com logoOHR Pharmaceutical Inc (OHRP) Short Interest Up 14.6% in March
www.americanbankingnews.com - April 13 at 12:34 PM
finance.yahoo.com logoOhr Pharmaceutical Provides Update on Squalamine Study
finance.yahoo.com - April 11 at 6:54 PM
americanbankingnews.com logoZacks: Brokerages Anticipate OHR Pharmaceutical Inc (OHRP) to Post -$0.30 Earnings Per Share
www.americanbankingnews.com - April 11 at 6:04 PM
rttnews.com logoAXON Names New CEO, ANTH Awaits Data In Q3, Nicox Gets 2nd Chance From FDA
www.rttnews.com - April 11 at 10:44 AM
streetinsider.com logoOhr Pharmaceutical (OHRP) Amends Trial of Squalamine in Wet-AMD to Enable Efficacy Analyses by End of 2017 or Early 2018
www.streetinsider.com - April 11 at 10:44 AM
finance.yahoo.com logoOhr Pharmaceutical Announces Closing of Public Offering of Common Stock and Warrants
finance.yahoo.com - April 10 at 6:33 PM
finance.yahoo.com logoOhr Pharmaceutical Provides Update on Ongoing Squalamine Clinical Trial in Wet-AMD
finance.yahoo.com - April 10 at 6:33 PM
finance.yahoo.com logoOhr Pharmaceutical Announces Proposed Public Offering of Common Stock and Warrants
finance.yahoo.com - April 7 at 11:42 AM
finance.yahoo.com logoOhr Pharmaceutical Announces Pricing of $14.175 Million Public Offering of Common Stock and Warrants
finance.yahoo.com - April 7 at 11:42 AM

Social

Chart

Ohr Pharmaceuticals (OHRP) Chart for Saturday, September, 23, 2017

This page was last updated on 9/23/2017 by MarketBeat.com Staff